Pilot Study of 19 Patients with Severe Pemphigus: Prophylactic Treatment with Rituximab Does Not Appear to be Beneficial

Publisher： Karger

E-ISSN： 1421-9832|228|2|158-165

ISSN： 1018-8665

Source： Dermatology, Vol.228, Iss.2, 2014-02, pp. : 158-165

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical and Immunological Follow-Up of Pemphigus Patients on Adjuvant Treatment with Immunoadsorption or Rituximab

By  

Dermatology, Vol. 218, Iss. 3, 2008-12 ,pp. : 237-245

Karger

Access to resources Recommend Favorite

Treatment of Refractory Pemphigus with the Anti-CD20 Monoclonal Antibody (Rituximab)

By  

Dermatology, Vol. 214, Iss. 4, 2007-04 ,pp. : 310-318

Karger

Access to resources Recommend Favorite

Assessment of the Effects of Rituximab Monotherapy on Different Subsets of Circulating T-Regulatory Cells and Clinical Disease Severity in Severe Pemphigus Vulgaris

By  

Dermatology, Vol. 232, Iss. 5, 2016-09 ,pp. : 572-577

Karger

Access to resources Recommend Favorite

Does Clinical Research Help Pemphigus Patients? Precautions and Suggestions

By  

Dermatology, Vol. 203, Iss. 3, 2001-11 ,pp. : 199-200

Karger

Access to resources Recommend Favorite

Efficacy of Dapsone in the Treatment of Pemphigus Vulgaris: A Single-Center Case Study

By  

Dermatology, Vol. 232, Iss. 5, 2016-10 ,pp. : 578-585

Karger

Access to resources Recommend Favorite